Skip to main content

RxNews®

Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.

Rinvoq® (upadacitinib), Rinvoq LQ (upadacitinib) – New formulation approval, New/expanded indications

April 26, 2024 - The FDA approved a new oral solution formulation of Novartis’ Rinvoq (upadacitinib) (brand name Rinvoq LQ).

Download PDF

 

Rx navigation